Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.20
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.80 (4.361%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Reminder to shareholders re. AGM voting

12 Jun 2023 07:00

RNS Number : 3234C
Novacyt S.A.
12 June 2023
 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Reminder to shareholders re. AGM voting

 

Paris, France and Eastleigh, UK - 12 June 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) exclusively as an open online meeting at 1pm BST/2pm CEST on Thursday, 15 June 2023. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary resolutions. All materials can be found at www.novacyt.com/investors.

 

The Board would like to strongly encourage shareholders to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

 

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions set out below.

 

Shareholders can vote in advance of the AGM by:

 

· Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it and returning it together with evidence of their shareholding which must be in the form of a share certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later than 12 June 2023 inclusive.

· Voting on-line using the Votaccess portal http://www.actionnaire.cic-marketsolutions.eu  if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 26 May 2023 to 14 June 2023 2pm BST/3pm CEST.

· Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

 

Shareholders can register for the AGM and access the online meeting by visiting www.novacytagm23.eventcaster.co.uk. Registrations must be accompanied by formal evidence of shareholding.

 

Following registration approval, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish, providing formal evidence of holding has been provided prior to the meeting.

 

Shareholders who have already voted (through a proxy, via their broker, nominee, bank, authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM but will not be able to vote twice.

 

Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors.

 

Contacts

 

Novacyt SA

+44 (0) 20 7756 1300

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470 

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Jack McLaren

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Paul McManus / Stephanie Cuthbert / Anna Dunphy

+44 (0)20 7933 8780

novacyt@walbrookpr.com

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing. 

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUASVROBUNAAR
Date   Source Headline
18th Mar 20226:00 pmRNSDirector/PCA Dealing
15th Mar 20222:30 pmRNSDirector/PDMR Shareholding
11th Mar 20228:00 amRNSHoldings in Company
1st Mar 20221:00 pmRNSLiquidity Agreement Update and Total Voting Rights
18th Feb 20224:05 pmRNSHoldings in Company
17th Feb 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
15th Feb 20224:00 pmRNSHoldings in Company
4th Feb 20227:00 amRNSLong Term Incentive Plan
1st Feb 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
25th Jan 20227:00 amRNSStrategy and Full Year 2021 Trading Update
4th Jan 20224:30 pmRNSLiquidity Agreement and Total Voting Rights
1st Dec 20212:30 pmRNSTotal Voting Rights
26th Nov 20217:00 amRNSApproval of COVID-19 test under CTDA legislation
2nd Nov 20217:00 amRNSValidation of COVID-19 tests in the UK under CTDA
1st Nov 20215:30 pmRNSLiquidity Agreement and Total Voting Rights
19th Oct 20214:15 pmRNSResults of annual general meeting
1st Oct 20212:30 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSR&D update
29th Sep 20215:00 pmRNSNotice of AGM
29th Sep 20217:00 amRNSNotice of rescheduled AGM
27th Sep 20217:00 amRNSHalf year 2021 results
16th Sep 20217:00 amRNSProposed accounting treatment of DHSC dispute
13th Sep 20217:00 amRNSAGM voting
1st Sep 202111:30 amRNSLiquidity Agreement and Total Voting Rights
20th Aug 20217:00 amRNSNotice of AGM
18th Aug 20217:00 amRNSHalf Year Update
5th Aug 20217:00 amRNSNotice of investor meeting
2nd Aug 20211:30 pmRNSTotal Voting Rights
29th Jul 20217:00 amRNSDavid Allmond to be CEO, Graham Mullis to retire
6th Jul 20212:40 pmRNSDirector/PDMR Shareholding
1st Jul 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Jun 20217:00 amRNSPublication of Annual Report
29th Jun 20217:00 amRNSExpansion of PathFlow COVID-19 LFT portfolio
22nd Jun 20217:00 amRNSFull year 2020 results and update on strategy
18th Jun 20217:00 amRNSUpdate on Notice of 2020 Full Year Results
3rd Jun 20217:00 amRNSLaunch of two new PCR COVID-19 assays
1st Jun 20212:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20217:00 amRNSLaunch of VersaLab Portable
21st May 20217:00 amRNSDHSC Dispute Update
17th May 20217:00 amRNSInclusion of SNPsig in the NHS England Framework
4th May 20211:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSNovacyt donates 1 million COVID-19 tests to UNICEF
23rd Apr 20217:00 amRNSR&D and UK operational update
22nd Apr 20217:00 amRNSNotice of Results
9th Apr 202112:30 pmRNSTrading Update
1st Apr 20211:40 pmRNSTotal Voting Rights
24th Mar 20217:00 amRNSLaunch of VariPLEX CE-Mark test
17th Mar 20217:11 amRNSLaunch of mobile processing laboratories
15th Mar 20214:45 pmRNSHoldings in Company
15th Mar 202111:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.